AOA Dx
Blood Test for Early Detection of Ovarian Cancer
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
AOA Dx is developing the next frontier in early-stage cancer detection for women through our pioneering work in glycolipids and proprietary biomarker technology. AOA Dx is a Y Combinator company (Summer 2021). YC-listed status: Active.
- Website
- aoadx.com
- Location
- Denver, CO, USA; Cambridge, MA, USA
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- GlycoLocate — AI-enabled multi-omics platform using lipidomics and proprietary biomarkers for early cancer detection in women. · Other
Links
- Y Combinator profileycombinator